SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Entera Bio Ltd. (ENTX) News

Track canonical SquawkNews coverage tagged to ENTX, Entera Bio Ltd.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 18 indexed stories across 11 publication days and is ordered by the same first-publication timeline used by LiveCast.

Symbol ENTX Asset equity Sector Markets 90 days 12 Last 2.755 Updated Sep 25, 2026, 01:07 PM UTC Open live news feed
L Entera Bio Price Target Announced at $11.00/Share by Guggenheim Ratings actions from Benzinga: GMT) Entera Bio Initiated at Buy by GuggenheimRatings actions from Benzinga NEWS | Sep 25, 2026, 01:07 PM UTC L Guggenheim initiates coverage of Entera Bio with Buy rating, $11 price target Guggenheim initiated coverage on Entera Bio's stock with a rating of Buy and a price target of $11.00.The price target implies an upside of 292.9% from the Sep 24 close of $2.80.Key takeaways from the analyst noteInnovat EQUITY | Sep 25, 2026, 01:03 PM UTC L Entera Bio initiated by Leerink with $9 target, Outperform rating Leerink Partners initiated coverage on Entera Bio Ltd. (ENTX) with an ‘Outperform’ rating and a $9 price target. ENTX closed at $3.03 per share on September 17, 2026. EQUITY | Sep 18, 2026, 12:21 PM UTC L ENTX - Correction: Entera to Participate in Upcoming Fall Investor Conferences ENTX - Correction: Entera to Participate in Upcoming Fall Investor Conferences EQUITY | Aug 27, 2026, 01:44 PM UTC L Entera to participate in upcoming fall investor conferences Entera says it will participate in upcoming fall investor conferences. EQUITY | Aug 27, 2026, 12:07 PM UTC L ENTX - Entera to Participate in Upcoming Fall Investor Conferences ENTX - Entera to Participate in Upcoming Fall Investor Conferences EQUITY | Aug 27, 2026, 12:02 PM UTC M ENTX files S-3 for 134,803,910 ordinary shares ENTX files Form S-3 covering 134,803,910 ordinary shares offered by the selling shareholders. REGULATION | Aug 21, 2026, 08:16 PM UTC L Entera appoints Riccardo Paolo Camisasca as Chief Medical Officer Entera (ENTX) appoints Riccardo Paolo Camisasca, M.D., as Chief Medical Officer ahead of planned EB613 Phase 3 initiation, according to a company release. REGULATION | Aug 18, 2026, 12:00 PM UTC M Entera Bio Presents Phase 2 Data on EB613 Entera Bio presents Phase 2 data on osteoporosis treatment EQUITY | Aug 04, 2026, 12:31 PM UTC L ENTX to Participate in Canaccord Conference ENTX to present at conference EQUITY | Jul 31, 2026, 08:30 PM UTC L ENTX ENTX - Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE ENTX ENTX - Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE EQUITY | Jul 29, 2026, 07:00 PM UTC L ENTX - Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement ENTX - Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement EQUITY | Jul 27, 2026, 12:31 PM UTC H NXTS Plunges 48% NXTS leads small cap negative movers premarket, down 48% on momentum, followed by WHLR, KIDZ, and others EQUITY | Jun 23, 2026, 12:22 PM UTC M Healthcare Stocks Move Gainers Catheter Precision (AMEX: VTAK ) shares rose 78.2% to $1.55 during Monday's after-market session. The company's market cap stands at $2.2 million. Allarity Therapeutics (NASDAQ: ALLR ) stock increased by 8.08% to EQUITY | Jun 22, 2026, 09:10 PM UTC M ENTX Receives FDA Feedback Entera Bio receives FDA's positive feedback for its Phase 3 registrational protocol for EB613 tablet to treat osteoporosis EARNINGS | Jun 22, 2026, 05:23 PM UTC M Healthcare Stocks Moving Multiple healthcare stocks are moving in Monday's intraday session, with gainers including Tenon Medical and Aditxt, and losers including Aethlon Medical and Atlantic International EQUITY | Jun 22, 2026, 05:23 PM UTC L ENTX Vol Pops ENTX volume is popping EQUITY | Jun 22, 2026, 04:16 PM UTC H ENTX Receives FDA Feedback ENTX - Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis EQUITY | Jun 22, 2026, 12:31 PM UTC